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Abstract
Background Cancer is a devastating disease and has
detrimental effects on the quality of life (QoL) of cancer
survivors and interferes with their treatment compliance.
The aim of the study is to assess resilience and QoL
among cancer survivors and to evaluate the important
factors affecting their resilience and QoL, with respect to
the Pakistani cultural context.
Method and analysis A cross-sectional study will be
conducted at a tertiary care hospital in Karachi, Pakistan.
A minimum sample size of 250 head and neck cancers
and 250 brain tumour survivors with 10% inflation for
non-response rate will be required. The SD of QoL and
resilience will range from 16.5 to 40.8 for head and neck
cancer, and 12.7 to 34.1 for brain tumour, at 5% level of
significance, with 2.5 precision. QoL will be assessed by
European Organization for Research and Treatment of
Cancer (EORTC) QLQ-C30, EORTC QLQ-H&N35 and EORTC
QLQ-BN20 and resilience will be evaluated by Wagnild
and Young’s 14-item scale. Mean±SD will be reported
for resilience and QoL scores. Unadjusted and adjusted
β-coefficients, with 95% CI, will be reported by using
multiple linear regression analysis. Correlation analysis
will also be performed using Pearson or Spearman
rank correlation coefficients. A p value of <0.05 will be
considered significant.
Ethics and dissemination Ethical approval has been
obtained from the Aga Khan University Pakistan’s Ethical
Review Committee. Written informed consent will be taken
from the participants by trained research assistants. A
trained psychologist will provide on-spot counselling to the
participants and those identified with severe depression
will be referred to a psychiatrist. The study materials will
be kept under lock and key and the electronic data base
will be password protected and will only be accessed by
the research team. The study findings will be disseminated
through publications conferences and workshops and
research briefs.
Trial registration number Clinicaltrials.gov registry
(NCT03466762).

Background
Globally, cancer is the second leading cause
of death.1 Approximately 70% of the deaths
from cancer occur in the lower middle

Strengths and limitations of this study
►► Validated measures will be used for evaluating the

outcomes and the independent variables.
►► The overall quality of the study will be maintained

through random spot-checks.
►► The study results can be generalised to all cancer

patients presenting at private tertiary care hospitals
in Pakistan.
►► To compare the quality of life and resilience within
the two groups of patients, subgroup analysis will be
performed by stratification.

income countries. Head and neck cancers
are the sixth most common cancers worldwide, with ~630 000 new cases diagnosed
annually, causing 350 000 deaths.2 3 Globally,
brain tumours are also a significant source of
cancer-related morbidity and mortality, with
an overall incidence of 4–5/100 000 cases
annually, contributing to 2% of all cancer
deaths.4 And in Pakistan ~150 000 new cases
of cancer are diagnosed annually, causing
60%–80% deaths.5
Conventionally, the endpoints of medical
care for cancer patients are focused on
survival rate, local control rate or complication rate.6 These assessments do not capture
the patients’ mental and emotional wellbeing,6 although the diagnosis of cancer
considerably affects a patient’s emotional and
psychological status7
Cancer patients suffer clinically important
symptoms of emotional distress such as
depression and anxiety8 that reduces their
quality of life (QoL) and resilience and interferes with their treatment compliance.9 10
Studies have found that cancer patients with
similar diseases and treatment status have
significantly different QoLs.11 12 It is believed
that resilience is the main factor that causes
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patients with similar situations to have different perceptions about their QoL.13 14
Resilience is an important trait that contributes to
a person’s mental and physical well-being. Evidence
suggests that resilience is related to motivation. This
motivation to recover from physical or psychological
traumatic events15 16 minimises the impact of risk factors,
thus increasing a person’s ability to deal with challenges
of life.17 Resilience, thus protects against psychosocial
health-related issues, such as depression, anxiety, fear and
helplessness, and helps to reduce their associated negative effects.18
Resilience has an important impact on the QoL of a
cancer patient. Hence, over the last few years, QoL has
become an important health-related outcome measure
with regard to communities and healthcare systems. This
outcome measure is based on multidimensional concept
that incorporates: the subjective perceptions of positive and negative aspects of cancer symptoms, physical,
emotional, social,cognitive functions, the disease symptoms and the side effects of treatment.7 19
There are several positive and negative factors that can
influence a cancer patient’s resilience and QoL. These
are: illness-related risk, which include perceived illness,
ambiguity and complexity, stress of symptoms, severity of
illness; family protective factors, which include perceived
social support from family and socioeconomic variables;
social protective factors, which include perceived social
support from friends, influence of others with similar
conditions and perceived support from providers; individual risk factors including evasive, emotive and fatalistic
coping measures/strategies; individual protective factors,

which include confrontive, optimistic and supportant
coping, along with hope and spiritual factors (figure 1).
Studies have examined the influence of psychological resilience among cancer patients.20 21 These studies
from different parts of the world suggest that resilience
is a protective factor against distress among cancer survivors22–26 which indicates that cancer patients with high
resilience require less psychosocial support to manage
their stressful conditions, as compared with those with low
resilience.20 One study reports that resilience mediates
between cancer symptoms and distress and QoL among
cancer survivors. Hence, resilience plays an important
role in protecting them against the adverse effects of
cancer symptoms.22 A systematic review of 24 studies on
head and neck cancer patients reports that distress-related variables (depression, anxiety and distress) have a
negative association with QoL outcomes.27
Moreover, resilience is a critical component for QoL
at all stages; during diagnosis, treatment, survivorship
and palliative care. It is an important trait for promoting
positive psychosocial well-being. Early identification
of psychological factors associated with post-treatment
QoL is essential among those at increased risk of poorer
outcomes, as this can aid in the development of interventions to improve their QoL.27
Limited evidence is available from the Pakistani context
regarding resilience and QoL among cancer patients. To
the best of the researchers’ knowledge, this will be the
first in-depth study to evaluate resilience and QoL among
head and neck cancer and brain tumour patients in Pakistan. Resilience and QoL among them changes over time
and may be modifiable towards increased well-being. This
study will, therefore, enable designing of interventions in
the future to improve resilience and QoL. In the light of
literature, the objectives of this study are:
1. To determine the resilience and the QoL scores for
head and neck cancer and brain tumour patients, at
least 4 weeks post-treatment.
2. To evaluate important factors associated with resilience
and QoL among head and neck cancer and brain tumour patients, at least 4 weeks post-treatment.
3. To examine the relationship between resilience and
the QoL for head and neck cancer and brain tumour
patients, at least 4 weeks post-treatment.
Methods
Study design
To evaluate resilience and QoL among head and neck
cancer and brain tumour patients and their associated factors an analytical cross-sectional study will be
conducted. Resilience and QoL will be measured at least
4 weeks post-treatment.

Figure 1 Conceptual framework of resilience and quality
of life for cancer survivors adapted from ‘the adolescent
resilience model’.47
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Study setting
The study will be conducted at the Aga Khan University
Hospital (AKUH) which is a Joint Commission International Accredition (JCIA-accredited) hospital, in
Zahid N, et al. BMJ Open 2019;9:e029084. doi:10.1136/bmjopen-2019-029084
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Karachi-Pakistan. Karachi is the largest metropolitan city
of Pakistan, a home to all major ethnicities living in this
country. Aga Khan University Hospital (AKUH) is one
of the largest private tertiary care hospitals that cater to
different ethnic and socioeconomic groups of population in Karachi. The participants will be recruited from
the surgical/oncology clinics at AKU. It has a multidisciplinary team that provides comprehensive care to cancer
patients. The proposed duration of data collection will be
4–6 months.
Study participants
Men and women aged 18 years and above, who have
received treatment for brain tumour and head and neck
cancer at AKUH, fulfilling the below eligibility criteria,
will be recruited. According to recent data, the prevalence of head and neck cancer is escalating in Pakistan
and limited information is available about their QoL
brain tumour also is an understudied area in Pakistan
and there is dearth of information regarding their QoL.
To maintain internal validity, the participants will be
studied based on assumptions pertaining to their respective group.
Eligibility criteria
Inclusion criteria
1. Individuals aged 18 years and above, who have received
treatment at AKUH for head and neck cancer or brain
tumour.
2. Cancer survivors living in Pakistan for at least 3 months.
3. Patients who will give consent to participate in the
study.

Figure 2

Participants recruitment plan flow diagram.

be coming in for their appointment, by the nurse. On the
day of appointment, the participants will be screened for
eligibility and if they fulfil the eligibility criteria and give
consent to participate, they will be enrolled in the study
(figure 2).
Sample size calculation
Head and neck cancer
The sample size has been calculated based on mean QoL
and resilience scores for head and neck cancer patients
from previous studies. It has been calculated using one
population mean formula, based on a SD range of 16.5–
40.8, 5% level of significance with precision of 2.5, and
by adjusting the sample size for 10% non-response rate.
The minimum sample size has been estimated to be
250.6 14 28–31

Exclusion criteria
1. Known cases of any psychiatric illness leading to disability (eg, manic disorder, schizophrenia and so on) as
confirmed by medical records, will be excluded from
the study as they may be on medications that might
distort the results.
2. Patients on antidepressants prescribed by a psychiatrist
3. Participants with physical comorbidities, stroke and
renal failure, will be excluded because these are debilitating diseases that will distort the results. Patients with
Cardiovascular Diseases (CVD)/heart disease, diabetes
or Chronic Obstructive Pulmonary Disease (COPD)
will not be excluded as every 4th Pakistani suffers from
cardiovascular risk factors. If patient with these conditions are excluded, the majority of the participants will
be ineligible and the required sample size will not be
achieved. However, these comorbid conditions will be
adjusted during analysis.

Brain tumour
The sample size has been calculated based on previously reported estimates for QoL and resilience among
patients with brain tumours. It has been calculated using
one population mean formula, based on a SD range of
12.7–34.1, 5% level of significance with precision of 2.5,
and by adjusting the sample size for 10% non-response
rate. The minimum sample size has been estimated to be
250.32–35

Sampling technique
Purposive sampling technique will be used for selecting
the participants. The target population, that is, brain
tumour and head and neck cancer patients who have
received cancer treatment, will be approached by
trained research assistants. The research assistants will be
informed about the possible study participants who will

Assessment tools
Resilience (Wagnild and Young’s 14 items)
Resilience is the ability to rebound or spring back, the
power of something to resume its original shape or position after compression or bending.36 Resilience is also
defined as the ‘capacity of individuals exposed to a negative event, to maintain stability and healthy physical and
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psychological functioning. It is a defense mechanism,
which permits people to grow in the face of adversity.’37
The resilience tool that will be used has two versions;
a long 25-item and short 14-item scale, using a 7-point
rating likert scale. It comprises the five core characteristics
of resilience, which include purposeful life, perseverance,
equanimity, self-reliance and existential loneliness.38 A
high score represents better resilience. The respondent’s
choice ranges from 1 (strongly disagree) to 7 (strongly
agree). The scale uses total scores rather than scores of
individual items. To measure resilience, the validated
Urdu version of the resilience scale 14 (RS-14), which
indicates moderate negative correlation of resilience with
depression and anxiety (r=−0.31), and moderate positive
significant correlation of resilience with life satisfaction
(r=0.40) will be used. The test–retest correlation coefficients and Cronbach’s alpha for RS-14 are 0.49 and 0.76,
respectively.39
QoL (EORTC QLQ-C30, EORTC QLQ-H&N35 and EORTC QLQ-BN20)
QoL is defined by the WHO as ‘Individual’s perceptions
of their position in life in the context of the culture and
value systems and their goals, expectations, standards
and concerns’.40 The QoL of the cancer survivors will
be assessed by the European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 tool.41 It is
composed of multi-item scales and single-item measures.
These include five functional scales, three symptom
scales, a global health status QoL scale and six single
items. All the scales and single-item measures scores
range from 0 to 100. A high score on the scale represents
a higher response level. Specific questionnaires will also
be administered to evaluate the QoL of patients with
brain tumours and head and neck cancer via EORTC
QLQ-BN20 and EORTC QLQ-H&N35, respectively. Since
the tool has not been validated in Urdu, therefore, in
this study content validation will be conducted through
a panel of experts and the content validity index (CVI)
will be calculated. The panel of experts will comprise
head and neck surgeons, neurosurgeons, an oncologist,
an epidemiologist, a biostatistician and a psychologist.
They will be asked to provide their expert suggestions
for improving the tool according to the Pakistani cultural
context, in Urdu. Each and every expert will rate the tool
regarding the relevancy and clarity of each question. The
responses will be rated on a scale from not relevant to
highly relevant. Based on expert scores, the CVI will be
calculated. CVI quantifies the level of content validity by
calculating the percentage agreement between experts.42
CVI of >0.8 indicates high level of agreement among the
experts.43 Permission has been granted by the QoL tool
developers for content validation.
Sociodemography and clinical characteristics
The information on demographic variables will be
collected on aspects like; age, gender, ethnicity, education, family status, number of people actively working,
monthly household income and employment status
4

of the individuals. The socioeconomic determinant
will include education, occupation and family income.
Information on comorbid conditions such as hypertension, diabetes, cardiovascular disease, addiction history
(including smoking and substance abuse) will also be
evaluated. Data on important major recent life events,
such as death of child, spouse or any other event that has
affected their lives will also be collected. Clinical characteristics and management of brain tumour and head and
neck cancer will also be assessed by taking information
from the patients on tumour type, site of tumour, type of
surgery, type of chemotherapy and/or radiotherapy.
Psychosocial characteristics
The participants’ depression and anxiety will be assessed
using the Hospital Anxiety and Depression Scale
(HADS),44and social support will be determined via the
Enriched Social Support Instrument (ESSI).9
Hospital anxiety and depression (HADS)
The Hospital Anxiety and Depression Scale (HADS) will
be administered to assess depression and anxiety among
the participants. This tool was developed to assess depression, anxiety and emotional distress among patients who
were treated for a variety of clinical problems. HADS
encompasses 14 items, equally subdivided into two
scales, one measuring anxiety and the other depression.
For instance, the item ‘Worrying thoughts go through
my mind’ assesses anxiety, whereas the item ‘I have lost
interest in my appearance’ evaluates depression. All the
responses are on an ordinal four-point scale.44 To measure
anxiety and depression, the Urdu version of HADS will be
used.45
Social support by ESSI
Social support can ease the coping process, or help
people overcome or adapt to a stressful event. The ESSI
is a 7-item scale that primarily measures functional social
support and emotional support. A total score of 18 or
less on items 1, 2, 3, 5 and 6 is considered as low social
support.9 To assess social support, the validated Urdu
version of ESSI, with a CVI for relevance, and clarity of
0.95 and 0.97, respectively, and Cronbach’s alpha 0.8246
will be used.
Explanatory questions to evaluate culturally relevant theme
Lastly, an explanatory questionnaire will be administered
to examine the factors that have affected the lives of the
cancer patients and also to examine the different coping
tactics used by the patients and their families to combat
this disease.
Statistical analysis
Analysis will be performed using the STATA V.12.
Descriptive statistics will be computed for categorical variables by computing their frequencies and percentages,
and the quantitative variables will be computed by their
mean±SD/median (IQR), as appropriate. Mean scores
will be reported for resilience and QoL. The multiple
Zahid N, et al. BMJ Open 2019;9:e029084. doi:10.1136/bmjopen-2019-029084
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linear regression technique will be used to evaluate the
effect of independent variables on the outcomes—resilience and QoL for head and neck patients and brain
tumour patients. Adjusted β-coefficients with 95% CI will
be reported. A p value of <0.05 will be considered statistically significant. To assess the relationship between
resilience and QoL, correlation analysis will also be
performed, using the Pearson or Spearman rank correlation coefficients as appropriate.
Ethical considerations
Participants will be recruited from the surgical/oncology
clinics of AKUH. Written informed consent will be taken
from the participants by trained research assistants, after
explaining the study procedure and its potential risks and
benefits to them.
In this particular study, the participants might feel
anxious/uncomfortable during the interview, especially
when their stress and depression level will be evaluated.
To overcome this, proper training will be given to the
research team for sensitive questions. On spot counselling
by a trained psychologist will be provided to the participants identified as having depression. Those patients
identified with severe depression especially with suicidal
intentions will be referred to a psychiatrist.
Strict confidentiality and privacy rules will be maintained and the participants’ information will be kept
confidential. Interviews will be conducted in a separate
room. All study materials containing personal identifiers
will be kept in a locked file cabinet. A unique study identification number will be assigned to each participant.
Data will be entered in a password-protected electronic
database that will only be accessible by the research team.
Patient and public involvement
This will be a cross-sectional study design and the participants will be interviewed, regarding their sociodemographic factors, anxiety, depression, resilience and QoL,
by trained research assistants.
The study findings will be disseminated to different
stakeholders, such as healthcare professionals, rehabilitation experts, psychologists and cancer patients through:
publications at local, national and international journals,
presentations at conferences and workshops and through
research briefs.
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